APO RESEARCH · REPORT
Drugs for Osteoarthritis Pain
Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.
Product & engineering
Understand the product.
Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.
Selected research
Industry Research
Drugs for Osteoarthritis Pain Industry Research Report 2026
Market perspective
Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis.
North America is the largest Drugs for Osteoarthritis Pain market with about 36% market share. Europe is follower, accounting for about 27% market share.
The key players are Pfizer, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma etc. Top 5 companies occupied about 66% market share.
Read the full market overview
Report Scope
This report quantifies the global Drugs for Osteoarthritis Pain market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Osteoarthritis Pain.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Osteoarthritis Pain Market by Company
Pfizer
Johnson & Johnson
GlaxoSmithKline
Bayer
Eli Lilly
Novartis
Sanofi
Horizon Pharma
Abbott
Mylan
Daiichi Sankyo
TEVA
Almatica Pharma
Astellas Pharma
Tide Pharmaceutical
Iroko Pharmaceuticals
Hengrui Pharmaceutical
Abiogen Pharma
Drugs for Osteoarthritis Pain Segment by Type
Oral
Injection
External
Drugs for Osteoarthritis Pain Segment by Application
Medical Care
Personal Care
Drugs for Osteoarthritis Pain Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Osteoarthritis Pain market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Osteoarthritis Pain and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Osteoarthritis Pain.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drugs for Osteoarthritis Pain companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injection
- External
Applications
- Medical Care
- Personal Care
Companies covered
- Pfizer
- Johnson & Johnson
- GlaxoSmithKline
- Bayer
- Eli Lilly
- Novartis
- Sanofi
- Horizon Pharma
- Abbott
- Mylan
- Daiichi Sankyo
- TEVA
- Almatica Pharma
- Astellas Pharma
- Tide Pharmaceutical
- Iroko Pharmaceuticals
- Hengrui Pharmaceutical
- Abiogen Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drugs for Osteoarthritis Pain by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 Injection
- 2.2.4 External
- 2.3 Drugs for Osteoarthritis Pain by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Medical Care
- 2.3.3 Personal Care
- 2.4 Assumptions and Limitations
3 Drugs for Osteoarthritis Pain Breakdown Data by Type
- 3.1 Global Drugs for Osteoarthritis Pain Historic Market Size by Type (2021-2026)
- 3.2 Global Drugs for Osteoarthritis Pain Forecasted Market Size by Type (2027-2032)
4 Drugs for Osteoarthritis Pain Breakdown Data by Application
- 4.1 Global Drugs for Osteoarthritis Pain Historic Market Size by Application (2021-2026)
- 4.2 Global Drugs for Osteoarthritis Pain Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drugs for Osteoarthritis Pain Market Perspective (2021-2032)
- 5.2 Global Drugs for Osteoarthritis Pain Growth Trends by Region
- 5.2.1 Global Drugs for Osteoarthritis Pain Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drugs for Osteoarthritis Pain Historic Market Size by Region (2021-2026)
- 5.2.3 Drugs for Osteoarthritis Pain Forecasted Market Size by Region (2027-2032)
- 5.3 Drugs for Osteoarthritis Pain Market Dynamics
- 5.3.1 Drugs for Osteoarthritis Pain Industry Trends
- 5.3.2 Drugs for Osteoarthritis Pain Market Drivers
- 5.3.3 Drugs for Osteoarthritis Pain Market Challenges
- 5.3.4 Drugs for Osteoarthritis Pain Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drugs for Osteoarthritis Pain Players by Revenue
- 6.1.1 Global Top Drugs for Osteoarthritis Pain Players by Revenue (2021-2026)
- 6.1.2 Global Drugs for Osteoarthritis Pain Revenue Market Share by Players (2021-2026)
- 6.2 Global Drugs for Osteoarthritis Pain Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drugs for Osteoarthritis Pain Head Office and Area Served
- 6.4 Global Drugs for Osteoarthritis Pain Players, Product Type & Application
- 6.5 Global Drugs for Osteoarthritis Pain Manufacturers Established Date
- 6.6 Global Drugs for Osteoarthritis Pain Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drugs for Osteoarthritis Pain Market Size (2021-2032)
- 7.2 North America Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drugs for Osteoarthritis Pain Market Size by Country (2021-2026)
- 7.4 North America Drugs for Osteoarthritis Pain Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drugs for Osteoarthritis Pain Market Size (2021-2032)
- 8.2 Europe Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drugs for Osteoarthritis Pain Market Size by Country (2021-2026)
- 8.4 Europe Drugs for Osteoarthritis Pain Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for Osteoarthritis Pain Market Size (2021-2032)
- 9.2 Asia-Pacific Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drugs for Osteoarthritis Pain Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drugs for Osteoarthritis Pain Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drugs for Osteoarthritis Pain Market Size (2021-2032)
- 10.2 South America Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drugs for Osteoarthritis Pain Market Size by Country (2021-2026)
- 10.4 South America Drugs for Osteoarthritis Pain Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for Osteoarthritis Pain Market Size (2021-2032)
- 11.2 Middle East & Africa Drugs for Osteoarthritis Pain Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drugs for Osteoarthritis Pain Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drugs for Osteoarthritis Pain Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer
- 12.1.1 Pfizer Company Information
- 12.1.2 Pfizer Business Overview
- 12.1.3 Pfizer Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.1.4 Pfizer Drugs for Osteoarthritis Pain Product Portfolio
- 12.1.5 Pfizer Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.2.4 Johnson & Johnson Drugs for Osteoarthritis Pain Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 GlaxoSmithKline
- 12.3.1 GlaxoSmithKline Company Information
- 12.3.2 GlaxoSmithKline Business Overview
- 12.3.3 GlaxoSmithKline Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.3.4 GlaxoSmithKline Drugs for Osteoarthritis Pain Product Portfolio
- 12.3.5 GlaxoSmithKline Recent Developments
- 12.4 Bayer
- 12.4.1 Bayer Company Information
- 12.4.2 Bayer Business Overview
- 12.4.3 Bayer Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.4.4 Bayer Drugs for Osteoarthritis Pain Product Portfolio
- 12.4.5 Bayer Recent Developments
- 12.5 Eli Lilly
- 12.5.1 Eli Lilly Company Information
- 12.5.2 Eli Lilly Business Overview
- 12.5.3 Eli Lilly Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.5.4 Eli Lilly Drugs for Osteoarthritis Pain Product Portfolio
- 12.5.5 Eli Lilly Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.6.4 Novartis Drugs for Osteoarthritis Pain Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Sanofi
- 12.7.1 Sanofi Company Information
- 12.7.2 Sanofi Business Overview
- 12.7.3 Sanofi Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.7.4 Sanofi Drugs for Osteoarthritis Pain Product Portfolio
- 12.7.5 Sanofi Recent Developments
- 12.8 Horizon Pharma
- 12.8.1 Horizon Pharma Company Information
- 12.8.2 Horizon Pharma Business Overview
- 12.8.3 Horizon Pharma Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.8.4 Horizon Pharma Drugs for Osteoarthritis Pain Product Portfolio
- 12.8.5 Horizon Pharma Recent Developments
- 12.9 Abbott
- 12.9.1 Abbott Company Information
- 12.9.2 Abbott Business Overview
- 12.9.3 Abbott Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.9.4 Abbott Drugs for Osteoarthritis Pain Product Portfolio
- 12.9.5 Abbott Recent Developments
- 12.10 Mylan
- 12.10.1 Mylan Company Information
- 12.10.2 Mylan Business Overview
- 12.10.3 Mylan Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.10.4 Mylan Drugs for Osteoarthritis Pain Product Portfolio
- 12.10.5 Mylan Recent Developments
- 12.11 Daiichi Sankyo
- 12.11.1 Daiichi Sankyo Company Information
- 12.11.2 Daiichi Sankyo Business Overview
- 12.11.3 Daiichi Sankyo Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.11.4 Daiichi Sankyo Drugs for Osteoarthritis Pain Product Portfolio
- 12.11.5 Daiichi Sankyo Recent Developments
- 12.12 TEVA
- 12.12.1 TEVA Company Information
- 12.12.2 TEVA Business Overview
- 12.12.3 TEVA Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.12.4 TEVA Drugs for Osteoarthritis Pain Product Portfolio
- 12.12.5 TEVA Recent Developments
- 12.13 Almatica Pharma
- 12.13.1 Almatica Pharma Company Information
- 12.13.2 Almatica Pharma Business Overview
- 12.13.3 Almatica Pharma Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.13.4 Almatica Pharma Drugs for Osteoarthritis Pain Product Portfolio
- 12.13.5 Almatica Pharma Recent Developments
- 12.14 Astellas Pharma
- 12.14.1 Astellas Pharma Company Information
- 12.14.2 Astellas Pharma Business Overview
- 12.14.3 Astellas Pharma Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.14.4 Astellas Pharma Drugs for Osteoarthritis Pain Product Portfolio
- 12.14.5 Astellas Pharma Recent Developments
- 12.15 Tide Pharmaceutical
- 12.15.1 Tide Pharmaceutical Company Information
- 12.15.2 Tide Pharmaceutical Business Overview
- 12.15.3 Tide Pharmaceutical Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.15.4 Tide Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio
- 12.15.5 Tide Pharmaceutical Recent Developments
- 12.16 Iroko Pharmaceuticals
- 12.16.1 Iroko Pharmaceuticals Company Information
- 12.16.2 Iroko Pharmaceuticals Business Overview
- 12.16.3 Iroko Pharmaceuticals Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.16.4 Iroko Pharmaceuticals Drugs for Osteoarthritis Pain Product Portfolio
- 12.16.5 Iroko Pharmaceuticals Recent Developments
- 12.17 Hengrui Pharmaceutical
- 12.17.1 Hengrui Pharmaceutical Company Information
- 12.17.2 Hengrui Pharmaceutical Business Overview
- 12.17.3 Hengrui Pharmaceutical Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.17.4 Hengrui Pharmaceutical Drugs for Osteoarthritis Pain Product Portfolio
- 12.17.5 Hengrui Pharmaceutical Recent Developments
- 12.18 Abiogen Pharma
- 12.18.1 Abiogen Pharma Company Information
- 12.18.2 Abiogen Pharma Business Overview
- 12.18.3 Abiogen Pharma Revenue in Drugs for Osteoarthritis Pain Business (2021-2026)
- 12.18.4 Abiogen Pharma Drugs for Osteoarthritis Pain Product Portfolio
- 12.18.5 Abiogen Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst